美托洛尔对急性心律失常患儿的疗效及对血清心肌酶和炎症因子的影响-东南大学学报医学版

美托洛尔对急性心律失常患儿的疗效及对血清心肌酶和炎症因子的影响

单位：华中科技大学同济医学院附属武汉儿童医院心血管内科, 湖北武汉 430019

分类号：R541.7

出版年·卷·期（页码）：2018·37·第六期（1037-1040）

摘要：

目的：分析美托洛尔对急性心律失常患儿的疗效及对血清心肌酶和炎症因子的影响。方法：收集2014年6月至2017年4月我院收治的急性心律失常患儿105例，分为予心肌营养治疗的对照组（51例）和给予美托洛尔治疗的观察组（54例），两组均治疗8周。记录患儿治疗前后心肌酶、炎症因子、心率变异指标、早搏改善情况，并观察比较两组的疗效。结果：治疗后，与对照组比，观察组血清心肌酶肌酸激酶（CK）、乳酸脱氢酶（LDH）、肌酸激酶同工酶（CK-MB）、天门冬氨酸氨基转移酶（AST）、丙氨酸氨基转移酶（ALT）、C-反应蛋白（CRP）、肿瘤坏死因子（TNF-α）、白介素-6（IL-6）、白介素-8（IL-8）明显降低（均P<0.05），窦性心搏RR间期标准差（SDNN）、5 min窦性心搏RR间期标准差均值（SDNNI）、5 min窦性心搏RR间期均值标准差（SDANN）、相邻窦性心搏RR间期差值均方根（RMSSD）及相邻窦性心搏RR间期差值4 h>50 ms所占比例（PNN50）明显增加（均P<0.05）。两组均无死亡病例。对照组早搏改善人数和临床疗效的总有效人数较观察组多（P<0.05）。不良反应发生率两组差异无统计学意义（P>0.05），但观察组不良反应有降低趋势。结论：美托洛尔治疗心律失常患儿疗效确切，其作用与降低血清心肌酶和炎症因子有关。

Objective:To investigate the effect of metoprolol on arrhythmia, serum myocardial enzymes and inflammatory factors. Methods:One hundred and five children with arrhythmia admitted in our hospital from June 2014 to April 2017 were enrolled in this study and randomly divided into 2 groups:51 cases was given myocardial nutrition therapy(control group) and 54 cases was given metoprolol(observation group). Both groups had been treated for 8 weeks. Serum myocardium enzymes, inflammatory factors, heart rate variability indicators, premature beat improvement were recorded before and after treatment and efficacy was compared between the two groups. Results:After treatment, compared with the control group, the levels of serum creatine kinase (CK), lactate dehydrogenase(LDH), creatine kinase-MB(CK-MB), alanine aminotransferase (ALT), aspartic transaminase(AST), C-reactiveprotein(CRP), tumor necrosis factor α (TNF-α), interleukin-6 (IL-6) and interleukin-8 (IL-8) had significantly decreased (all P<0.05), heart rate variability indicators SDNN, SDNNI, SDANN, RMSSD and PNN50 had significantly increased(all P<0.05) in the observation group. There was no deaths in the two groups. The cases of improvement of premature beats and total effective patients in the observation group were more than those in the control group (P<0.05). There was no significant difference of side effectes between the two groups (P>0.05). Conclusion:Metoprolol is effective in the treatment of child arrhythmia, which is related to decreasing of serum myocardial enzymes and inflammatory factors.

参考文献：

[1] 石琳.冠心病心律失常采用美托洛尔联合稳心颗粒治疗的临床观察[J].中国医药指南,2014,28(17):314-315.
[2] 王耀明,曹亚船,徐庄剑,等.21例新生儿心律失常临床特点、治疗及预后分析[J].江苏医药,2017,43(9):672-674.
[3] 金文杰.阿托伐他汀联合缬沙坦对永久性房颤患者心脏重构及炎症因子水平的影响[J].现代医学,2016,44(10):1399-1402.
[4] DRAGO F,BATTIPAGLIA I,di MAMBRO C.Neonatal and pediatric arrhythmias:clinical and electrocardiographic aspects[J].Card Electrophysiol Clin,2018,10(2):397-412.
[5] 梁福攸,张宗绵,叶文华,等.β受体阻滞剂美托洛尔对于脓毒血症患者心脏保护作用[J].现代诊断与治疗,2015,26(4):733-735.
[6] 李立学.普罗帕酮联合美托洛尔治疗先天性心脏病诱发小儿心律失常的疗效研究[J].临床合理用药杂志,2015,8(30):18-19.
[7] 王春玲,陈阿娣,田亮,等.大剂量西地兰联合小剂量酒石酸美托洛尔治疗急性左心衰并心房颤动的临床疗效[J].现代医学,2016,44(7):1014-1017.
[8] 任光萍.美托洛尔联合普罗帕酮治疗小儿心律失常的疗效观察[J].中西医结合心血管病电子杂志,2015,3(28):31-32.
[9] 何超凡.胺碘酮联合美托洛尔治疗房颤并心衰的疗效观察[J].中国现代药物应用,2017,11(2):84-86.

服务与反馈：

【文章下载】【发表评论】【查看评论】【加入收藏】

提示：您还未登录，请登录！点此登录